Assenagon Asset Management S.A. Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Assenagon Asset Management S.A. boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,715 shares of the company’s stock after purchasing an additional 793 shares during the period. Assenagon Asset Management S.A. owned approximately 0.07% of Medpace worth $7,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Stone House Investment Management LLC purchased a new position in Medpace in the third quarter worth $33,000. Ashton Thomas Securities LLC acquired a new stake in shares of Medpace in the third quarter worth $37,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace during the 3rd quarter valued at about $46,000. True Wealth Design LLC boosted its position in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Medpace by 95.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock worth $93,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.2 %

Shares of MEDP opened at $337.35 on Monday. The firm has a market capitalization of $10.48 billion, a P/E ratio of 29.54, a price-to-earnings-growth ratio of 1.80 and a beta of 1.36. Medpace Holdings, Inc. has a twelve month low of $284.32 and a twelve month high of $459.77. The stock’s fifty day simple moving average is $340.52 and its 200 day simple moving average is $356.98.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 earnings per share. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Truist Financial dropped their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday, November 25th. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.